PD Dr. Jan-Henning Klusmann is a co-winner of the 2017 Robert J. Arceci Award, a unique prize that offers resources and freedom to pioneers and innovators in childhood cancer research.
We provide a non-coding RNA expression atlas across normal and malignant blood formation. Our data highlight the biological and clinical importance of ncRNAs, and the necessity of further functional studies.
Two publications in one day: 1) Leveraging the CRISPR-Cas9 system to accurately model translocation-driven leukemogenesis yields new insights into the importance of environmental cues in disease induction.
Two publications in one day: 2) Targeted gene correction in induced pluripotent stem cells from Kostmann disease patients reverted the disease phenotype and rescued granulocytic function.
We are looking for an enthusiastic, proactive and creative team player capable of developing and performing experiments independently. Experience with tissue culture and molecular biology preferred.
Results from the international ML-DS 2006 trial indicate that children with Down syndrome acute myeloid leukemia can be cured with a less intensive, less cytotoxic treatment regime.
All five of our PhD students showed posters at the ISALXVI in Munich. Dorit was further selected as a Best of Free Contributions and gave a talk and interview about her research.
Congratulations to Dr. rer. nat. Erik Pittermann, who has graduated from the Regenerative Sciences PhD program (HBRS/REBIRTH Cluster of Excellence) with a magna cum laude.
Congratulations to Dr. Razan Jammal, who graduated today from the HBRS Molecular Medicine PhD program. She successfully defended her thesis and received a magna cum laude.
Eight of our students presented their work this year at the 29th Annual Kind Philipp Meeting in Wilsede. Michelle received the first Kind Philipp Presentation Award for unpublished research.